Sanders Williams - Amgen Independent Director
| AMGN Stock | USD 277.37 3.43 1.25% |
Director
Dr. R. Sanders Williams, M.D., is an Independent Director of the Company. R. Sanders Williams is President of Gladstone Institutes, a nonprofit biomedical research enterprise, and its Robert W. and Linda L. Mahley Distinguished Professor of Medicine, both since 2010. He is also a Professor of Medicine at the University of California, San Francisco since 2010. Prior to this, Dr. Williams served as Senior Vice Chancellor of the Duke University School of Medicine from 2008 to 2010 and Dean of the Duke University School of Medicine from 2001 to 2008. Dr. Williams was the founding Dean of the DukeNUS Graduate Medical School, Singapore, from 2003 to 2008 and served on its Governing Board from 2003 to 2010. From 1990 to 2001, Dr. Williams was Chief of Cardiology and Director of the Ryburn Center for Molecular Cardiology at the University of Texas, Southwestern Medical Center. Dr. Williams was a director of the Laboratory Corporation of America Holdings, a diagnostic technologies company, since 2007, serving on the Audit Committee and chairing the Quality and Compliance Committee. Dr. Williams was a director of BristolMyers Squibb Company, a pharmaceutical company, from 2006 until 2013. Dr. Williams has served on the board of directors of the Gladstone Foundation, a nonprofit institution that is distinct from Gladstone Institutes, since 2012 and on the board of directors of Exploratorium, a nonprofit science museum and learning center located in San Francisco, since 2011. Dr. Williams was elected to the National Academy of Medicine in 2002 since 2014.
| Age | 69 |
| Tenure | 10 years |
| Address | One Amgen Center Drive, Thousand Oaks, CA, United States, 91320-1799 |
| Phone | 805 447 1000 |
| Web | https://www.amgen.com |
Amgen Management Efficiency
The company has return on total asset (ROA) of 0.0629 % which means that it generated a profit of $0.0629 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of 1.3579 %, meaning that it created $1.3579 on every $100 dollars invested by stockholders. Amgen's management efficiency ratios could be used to measure how well Amgen manages its routine affairs as well as how well it operates its assets and liabilities. At this time, Amgen's Return On Assets are very stable compared to the past year. As of the 1st of May 2024, Return On Equity is likely to grow to 1.13, while Return On Tangible Assets are likely to drop 0.12. At this time, Amgen's Return On Assets are very stable compared to the past year. As of the 1st of May 2024, Asset Turnover is likely to grow to 0.51, while Other Current Assets are likely to drop about 266.9 M.Similar Executives
| Showing other executives | DIRECTOR Age | ||
| Edward Liddy | AbbVie Inc | 75 | |
| Susan Hockfield | Pfizer Inc | 70 | |
| John Noseworthy | Merck Company | 66 | |
| Richard Whitley | Gilead Sciences | 72 | |
| Alan Lacy | Bristol Myers Squibb | 64 | |
| Wyllie Cornwell | Pfizer Inc | 71 | |
| William Burnside | AbbVie Inc | 69 | |
| Matthew Emmens | Bristol Myers Squibb | 68 | |
| Inge Thulin | Merck Company | 67 | |
| Raul Alvarez | Eli Lilly and | 65 | |
| Rochelle Lazarus | Merck Company | 71 | |
| Scott Davis | Johnson Johnson | 66 | |
| William Perez | Johnson Johnson | 71 | |
| Scott Gottlieb | Pfizer Inc | 48 | |
| Robert Pangia | Biogen Inc | 66 | |
| Frances Fergusson | Pfizer Inc | 71 | |
| Frederick Waddell | AbbVie Inc | 67 | |
| Kevin Lofton | Gilead Sciences | 63 | |
| Paul Rothman | Merck Company | 63 | |
| Carolyn Bertozzi | Eli Lilly and | 53 | |
| Hubert Joly | Johnson Johnson | 61 | |
Management Performance
| Return On Equity | 1.36 | ||||
| Return On Asset | 0.0629 |
Amgen Inc Leadership Team
Elected by the shareholders, the Amgen's board of directors comprises two types of representatives: Amgen inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Amgen. The board's role is to monitor Amgen's management team and ensure that shareholders' interests are well served. Amgen's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Amgen's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Linda Louie, VP Officer | ||
| James MD, Executive Officer | ||
| Frank Herringer, Independent Director | ||
| Nancy Grygiel, Senior Officer | ||
| Francois Carbonnel, Independent Director | ||
| Rebecca Henderson, Independent Director | ||
| Annette Such, Chief Accounting Officer | ||
| Sanders Williams, Independent Director | ||
| Vance Coffman, Lead Independent Director | ||
| David Reese, Executive Vice President - Research and Development | ||
| Tyler Jacks, Independent Director | ||
| Brian McNamee, Executive Vice President - Full Potential Initiatives | ||
| Gregory Garland, Independent Director | ||
| Charles Holley, Director | ||
| Esteban Santos, Executive Vice President Operations | ||
| Jonathan Graham, Senior Vice President General Counsel, Secretary | ||
| Sean Harper, Executive Vice President - Research and Development | ||
| Mike Zahigian, Senior Officer | ||
| Ellen Kullman, Director | ||
| Frank Biondi, Independent Director | ||
| Arvind Sood, IR Contact Officer | ||
| David Meline, CFO and Executive VP | ||
| Ronald Sugar, Independent Director | ||
| Stuart Tross, Senior Vice President - Human Resources | ||
| Robert Bradway, Chairman, CEO and President Chairman of Executive Committee and Member of Equity Award Committee | ||
| Murdo Gordon, Executive Vice President of Global Commercial Operations | ||
| Peter Griffith, Executive CFO | ||
| Wanda Austin, Independent Director | ||
| Robert Eckert, Independent Director | ||
| Madhavan Balachandran, Executive VP of Operations | ||
| Lori Johnston, Senior Vice President - Human Resources | ||
| Brian Druker, Independent Director | ||
| Cynthia Patton, Senior Vice President Chief Compliance Officer | ||
| Greg Garland, Independent Director | ||
| Robert Williams, Independent Director | ||
| Justin Claeys, Vice Relations | ||
| Matthew Busch, Chief Finance | ||
| Judith Pelham, Independent Director | ||
| David Baltimore, Independent Director | ||
| Fred Hassan, Director | ||
| David Piacquad, Senior Vice President - Business Development | ||
| Anthony Hooper, Executive VP of Global Commercial Operations | ||
| Alan Russell, Vice Biologics | ||
| David MD, Executive Officer |
Amgen Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Amgen a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | 1.36 | ||||
| Return On Asset | 0.0629 | ||||
| Profit Margin | 0.24 % | ||||
| Operating Margin | 0.08 % | ||||
| Current Valuation | 201.29 B | ||||
| Shares Outstanding | 536.38 M | ||||
| Shares Owned By Insiders | 0.25 % | ||||
| Shares Owned By Institutions | 80.58 % | ||||
| Number Of Shares Shorted | 10.11 M | ||||
| Price To Earning | 22.74 X |
Pair Trading with Amgen
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Amgen position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Amgen will appreciate offsetting losses from the drop in the long position's value.Moving together with Amgen Stock
| 0.64 | EWTX | Edgewise Therapeutics Financial Report 9th of May 2024 | PairCorr |
Moving against Amgen Stock
| 0.75 | VKTX | Viking Therapeutics | PairCorr |
| 0.75 | KRYS | Krystal Biotech Financial Report 13th of May 2024 | PairCorr |
| 0.72 | LLY | Eli Lilly | PairCorr |
| 0.72 | HCWB | HCW Biologics | PairCorr |
| 0.66 | OGN | Organon Financial Report 2nd of May 2024 | PairCorr |
The ability to find closely correlated positions to Amgen could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Amgen when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Amgen - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Amgen Inc to buy it.
The correlation of Amgen is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Amgen moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Amgen Inc moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Amgen can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Amgen Inc. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in price. Note that the Amgen Inc information on this page should be used as a complementary analysis to other Amgen's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Portfolio Manager module to state of the art Portfolio Manager to monitor and improve performance of your invested capital.
Complementary Tools for Amgen Stock analysis
When running Amgen's price analysis, check to measure Amgen's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Amgen is operating at the current time. Most of Amgen's value examination focuses on studying past and present price action to predict the probability of Amgen's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Amgen's price. Additionally, you may evaluate how the addition of Amgen to your portfolios can decrease your overall portfolio volatility.
| Sectors List of equity sectors categorizing publicly traded companies based on their primary business activities | |
| Correlation Analysis Reduce portfolio risk simply by holding instruments which are not perfectly correlated | |
| Global Markets Map Get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes | |
| Analyst Advice Analyst recommendations and target price estimates broken down by several categories | |
| Sync Your Broker Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors. | |
| Sign In To Macroaxis Sign in to explore Macroaxis' wealth optimization platform and fintech modules | |
| Portfolio Comparator Compare the composition, asset allocations and performance of any two portfolios in your account | |
| My Watchlist Analysis Analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like | |
| Equity Search Search for actively traded equities including funds and ETFs from over 30 global markets | |
| Transaction History View history of all your transactions and understand their impact on performance | |
| Portfolio Rebalancing Analyze risk-adjusted returns against different time horizons to find asset-allocation targets |
Is Amgen's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Amgen. If investors know Amgen will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Amgen listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth (0.52) | Dividend Share 8.52 | Earnings Share 12.5 | Revenue Per Share 52.692 | Quarterly Revenue Growth 0.198 |
The market value of Amgen Inc is measured differently than its book value, which is the value of Amgen that is recorded on the company's balance sheet. Investors also form their own opinion of Amgen's value that differs from its market value or its book value, called intrinsic value, which is Amgen's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Amgen's market value can be influenced by many factors that don't directly affect Amgen's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Amgen's value and its price as these two are different measures arrived at by different means. Investors typically determine if Amgen is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Amgen's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.